Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chuk Chui Man is active.

Publication


Featured researches published by Chuk Chui Man.


Journal of Medicinal Chemistry | 2009

Structure-Based Optimization of Arylamides as Inhibitors of Soluble Epoxide Hydrolase

Anne B. Eldrup; Fariba Soleymanzadeh; Steven John Taylor; Ingo Muegge; Neil A. Farrow; David B. Joseph; Keith McKellop; Chuk Chui Man; Alison Kukulka; Stéphane De Lombaert

Inhibition of soluble epoxide hydrolase (sEH) is hypothesized to lead to an increase in circulating levels of epoxyeicosatrienoic acids, resulting in the potentiation of their in vivo pharmacological properties. As part of an effort to identify inhibitors of sEH with high and sustained plasma exposure, we recently performed a high throughput screen of our compound collection. The screen identified N-(3,3-diphenyl-propyl)-nicotinamide as a potent inhibitor of sEH. Further profiling of this lead revealed short metabolic half-lives in microsomes and rapid clearance in the rat. Consistent with these observations, the determination of the in vitro metabolic profile of N-(3,3-diphenyl-propyl)-nicotinamide in rat liver microsomes revealed extensive oxidative metabolism and a propensity for metabolite switching. Lead optimization, guided by the analysis of the solid-state costructure of N-(3,3-diphenyl-propyl)-nicotinamide bound to human sEH, led to the identification of a class of potent and selective inhibitors. An inhibitor from this class displayed an attractive in vitro metabolic profile and high and sustained plasma exposure in the rat after oral administration.


Bioorganic & Medicinal Chemistry Letters | 2009

Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design

Brian Nicholas Cook; Jörg Bentzien; Andre White; Peter Allen Nemoto; Ji Wang; Chuk Chui Man; Fariba Soleymanzadeh; Hnin Hnin Khine; Mohammed A. Kashem; Stanley Kugler; John P. Wolak; Gregory P. Roth; Stephane De Lombaert; Steven S. Pullen; Hidenori Takahashi

Interleukin-2 inducible T-cell kinase (ITK) is a member of the Tec kinase family and is involved with T-cell activation and proliferation. Due to its critical role in acting as a modulator of T-cells, ITK inhibitors could provide a novel route to anti-inflammatory therapy. This work describes the discovery of ITK inhibitors through structure-based design where high-resolution crystal structural information was used to optimize interactions within the kinase specificity pocket of the enzyme to improve both potency and selectivity.


Bioorganic & Medicinal Chemistry Letters | 2010

Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.

Ho Yin Lo; Chuk Chui Man; Roman Wolfgang Fleck; Neil A. Farrow; Richard H. Ingraham; Alison Kukulka; John R. Proudfoot; Raj Betageri; Tom Kirrane; Usha R. Patel; Rajiv Sharma; Mary Ann Hoermann; Alisa Kabcenell; Stephane De Lombaert

A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent sEH inhibitors with favorable CYP3A4 inhibitory and microsomal stability profiles.


Tetrahedron Letters | 2008

2-Aminobenzimidazoles as potent ITK antagonists: de novo design of a pyrrole system targeting additional hydrogen bonding interaction

Ho Yin Lo; Jörg Bentzien; Andre White; Chuk Chui Man; Roman Wolfgang Fleck; Steven S. Pullen; Hnin Hnin Khine; Josephine King; Joseph R. Woska; John P. Wolak; Mohammed A. Kashem; Gregory P. Roth; Hidenori Takahashi


Archive | 2006

Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors

Roman Wolfgang Fleck; Xin Guo; Ho Yin Lo; Chuk Chui Man


Archive | 2005

Tec kinase inhibitors

Joerg Martin Bentzien; Brian Nicholas Cook; Xiang Li; Ho Yin Lo; Chuk Chui Man; Ingo Andreas Mugge; Peter Allen Nemoto; Steven S. Pullen; Doris Riether; Gregory P. Roth; Fariba Soleymanzadeh; Hidenori Takahashi; Ji Wang; Andre White; Renee M. Zindell


Archive | 2005

Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders

Joerg Martin Bentzien; Brian Nicholas Cook; Xiang Li; Ho Yin Lo; Chuk Chui Man; Ingo Andreas Mugge; Steven S. Pullen; Gregory P. Roth; Fariba Soleymanzadeh; Hidenori Takahashi; Ji Wang; Andre White; Renee M. Zindell; Doris Riether; Peter Allen Nemoto; Xin Yao; John E. Mangette


Archive | 2008

Benzimidazolone Chymase Inhibitors

Asitha Abeywardane; Brian Nicholas Cook; Stephane De Lombaert; Michel J. Emmanuel; Xin Guo; Ming-Hong Hao; Jin Mi Kim; Ho Yin Lo; Chuk Chui Man; Tina Marie Morwick; Peter Allen Nemoto; Kevin Chungeng Qian; Hidenori Takahashi; Steven John Taylor


Archive | 2011

Biarylamide inhibitors of leukotriene production

Angela Berry; Zhidong Chen; Stephane De Lombaert; Michel J. Emmanuel; Pui Leng Loke; Chuk Chui Man; Tina Marie Morwick; Hidenori Takahashi


Archive | 2008

Quinazolinedione chymase inhibitors

Xin Guo; Ho Yin Lo; Chuk Chui Man; Hidenori Takahashi

Collaboration


Dive into the Chuk Chui Man's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xin Guo

Boehringer Ingelheim

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge